A look at the 100–500 kHz alternating fields (FDA-approved for specific oncological indications) that researchers study for their effects on cell division – and how they fundamentally differ from Rife machines.
Evidence-Based vs. Historical Theory
Rife frequencies (1930s) and TTFields (2010s) are both based on the principle that electrical frequencies can act on cells. The decisive difference: Rife has no Phase III human data. TTFields has FDA approval.
TTFields were developed by the Israeli physicist Yoram Palti and approved by the FDA for glioblastoma in 2011 – following a regulatory approval pathway of the highest evidence category (Premarket Approval). This fundamentally distinguishes TTFields from experimental or traditional frequency therapies.
The Mechanism: Disruption of the Mitotic Spindle
TTFields operate at 100–300 kHz – significantly higher than audible frequencies. In this range, polar molecules (especially tubulin dimers) react to the alternating electric field and are aligned in the direction of the field.
During mitosis (cell division), tubulin polymers must precisely build the mitotic spindle. TTFields are hypothesized to physically disrupt this alignment → leading to faulty chromosome distribution → apoptosis (programmed cell death) of affected cells. Healthy cells, which divide more slowly, appear to be less significantly affected.
Clinical Results in Glioblastoma
Grade IV Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of ~15 months under standard therapy (Stupp protocol: surgery + radiation + Temozolomide).
EF-14 study (Stupp et al., JAMA 2017, n=695):
- Median overall survival: 20.9 months (TTFields + TMZ) vs. 16.0 months (TMZ alone)
- 2-year survival: 43% vs. 29%
- 5-year survival: 13% vs. 5%
- Only significant side effect: local skin irritation from electrode patches
The Future: Additional Tumor Types
TTFields are now in clinical trials for pleural mesothelioma (FDA-approved 2019) and other tumor types. The principle is being studied across multiple indications – researchers are investigating whether actively dividing cells are generally targetable. The combination with immunotherapies (checkpoint inhibitors) is being intensively studied.
Dieser Artikel dient ausschließlich der Information und Bildung. Er ersetzt keine medizinische Diagnose oder Behandlung. Es werden keine Heilversprechen gegeben. Anwendung auf eigenes Risiko. Medical Disclaimer lesen →